Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.As of 11 Jun 2026, Caplin Point Lab share price is ₹2,338.00. The stock opened at ₹2,309.40, compared to its previous close of ₹2,309.40. During today's trading session, Caplin Point Lab share price moved in the range of ₹2,291.10 to ₹2,375.00, with an average price of ₹2,333.05 for the day. Looking at its last 52-week, the stock has touched a low of ₹2,291.10 and a high of ₹2,375.00. On the performance front, Caplin Point Lab share price has increased by 19.42% over the last six months and is up 10.15% on a year-on-year basis.
The market capitalization of Caplin Point Lab is ₹17,544 Crs, with a P/E ratio of 27.0 and a dividend yield of 0.17%.